Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7251 USD | -7.05% | -3.78% | +29.48% |
Apr. 23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
Apr. 23 | Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+29.48% | 78.25M | |
+2.36% | 42.75B | |
+47.75% | 41.61B | |
+12.37% | 41.34B | |
-12.36% | 26.59B | |
+8.51% | 25.49B | |
-23.43% | 18.12B | |
+30.52% | 12.24B | |
-1.77% | 11.76B | |
+8.40% | 11B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Life Sciences Initiates Phase 2a Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis